# Appendix C: Source Provenance and Publication Controls

## Purpose

This appendix prevents the resource from gradually turning provisional clinical synthesis into fake settled science through repetition. Each public claim should retain its evidence class, source ID, population, compound, and last-verified date.

## Compound naming controls

Do not use **kratom**, **mitragynine**, **7-OH**, **mitragynine pseudoindoxyl**, **MGM-15**, **MGM-16**, and **commercial kratom-derived product** as interchangeable terms.

Use:

- **botanical kratom** for minimally processed *Mitragyna speciosa* leaf;
- **MG-rich extract** for an extract dominated by mitragynine;
- **concentrated 7-OH product** when 7-OH is labeled or analytically demonstrated at enhanced concentration;
- **commercial kratom-derived product** when composition is unknown or mixed;
- **MP, MGM-15, or MGM-16** only when specifically identified or declared;
- **reported 7-OH exposure** when the claim rests on patient history without analytical confirmation.

## Evidence wording controls

| Evidence | Preferred wording | Avoid |
|---|---|---|
| Controlled human | "A controlled human study found…" | "Proves universally…" |
| Small series | "In a nine-patient retrospective series…" | "Clinical trials show…" |
| Case report | "A published case described…" | "7-OH causes…" without qualification |
| Animal/in-vitro | "In rats/in a receptor assay…" | Human dose or incidence conversion |
| Practice experience | "In the author's clinical experience…" | "Data show…" |
| No direct data | "Data insufficient" | Filling the blank with botanical analogy |

## High-risk recurring errors

1. Calling the July 2026 DEA notice a final federal Schedule I order before an order is published.
2. Presenting California's food/drug enforcement position as a controlled-substance schedule listing.
3. Calling 7-OH a weak partial agonist without noting assay and receptor-reserve dependence.
4. Treating G-protein bias as proof of respiratory safety.
5. Inventing a gamma opioid receptor.
6. Attributing serotonin or stimulant pharmacology of botanical minor alkaloids directly to purified 7-OH.
7. Publishing a universal 7-OH half-life or urine-detection window.
8. Turning the provisional 16-36-hour peak estimate into a validated time-course claim.
9. Using a fixed clock as the sole criterion for buprenorphine induction.
10. Calling every seizure, psychosis, QT change, or liver injury a proven isolated-7-OH effect.
11. Treating consultation cases as equivalent to directly treated cohort cases.
12. Describing the uploaded 2024 predecessor CSAM deck as the author's 2025 presentation.

## Legal update procedure

Record the exact source, action type, publication date, effective date, threshold, and jurisdiction. Search separately for a notice, proposed rule, temporary order, final rule, statute, administrative rule, and health-department enforcement notice. A search failure is not proof of absence; wording should say a later order "was not located in the sources checked as of [timestamp]."

## Correction policy

Material corrections require:

- a dated changelog entry;
- the prior wording and replacement wording;
- the source that triggered the correction;
- whether the change affects clinical advice, legal status, or only terminology;
- prompt correction across all derivative pages, infographics, and decks.

## Author-content provenance

The official CSAM 2025 course page verifies Brian Harris, MD as faculty for Basic Science (Neurobiology) and Legal Aspects of Addiction Medicine. His report that the lecture included a dedicated emerging-opioids/7-OH segment is author-reported unless the final 2025 presentation is archived. The currently uploaded PowerPoint parses as a 2024 predecessor deck attributed to Waseem Khader and is useful as curricular context, not proof of the later lecture's exact content.